Criteria for metabolic syndrome (MetS) in subjects with and without RA who did not have cardiovascular disease.
| Criteria† | RA (n = 232), n (%) | Non-RA (n = 1241), n (%*) | Odds Ratio (95% CI) Adjusted for Age and Sex | p |
|---|---|---|---|---|
| Increased waist circumference | 127 (54) | 432 (35/40) | 2.3 (1.7, 3.1) | < 0.001 |
| Elevated triglycerides or treatment** | 64 (30) | 321 (35/28) | 0.8 (0.6, 1.2) | 0.26 |
| Reduced HDL or treatment** | 50 (24) | 198 (22/16) | 1.2 (0.8, 1.7) | 0.43 |
| Elevated blood pressure or treatment | 135 (58) | 725 (58/47) | 1.5 (1.1, 2.1) | 0.02 |
| Elevated fasting glucose or treatment*** | 64 (32) | 355 (37/28) | 1.0 (0.7, 1.4) | 0.96 |
| Metabolic syndrome (≥ 3 of 5 criteria) | 76 (33) | 316 (25/20) | 1.6 (1.2, 2.2) | 0.002 |
↵† MetS was defined using the national Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria as affirmed and slightly modified by the American heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI)14. MetS definition requires any 3 of 5 criteria: increased waist circumference (≥ 102 cm in non-Asian men, ≥ 88 cm in non-Asian women, ≥ 90 cm in Asian men, ≥ 80 cm in Asian women), elevated triglycerides (≥ 150 mg/dl or treatment with fibrates or nicotinic acid), reduced high-density cholesterol (HDL < 40 mg/dl in men or < 50 mg/dl in women or treatment with fibrates or nicotinic acid), elevated blood pressure (≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or treatment for hypertension), or elevated fasting glucose (≥ 100 mg/dl or treatment for elevated glucose).
↵* Non-RA percentages are presented raw and adjusted to age and sex distribution of RA subjects.
↵** Lipid measures were not available in 21 RA and 324 non-RA subjects.
↵*** Glucose measures were not available in 35 RA and 284 non-RA subjects. HDL: high-density lipoprotein cholesterol.